ArticleFrontiers in oncology2026

Ascomycin enhances the antitumor activity of osimertinib in EGFR-TKI-resistant non-small cell lung cancer.

Hongbing Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.